Chronic lymphocytic leukemia
Conditions
Interventions
None:None
Sponsors
The First Affiliated Hospital, Zhejiang University College of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. CLL/SLL patients who have not reached the treatment indications 2. Obtain informed consent signed by the patient or family members
Exclusion criteria
Exclusion criteria: 1. Indications of disease progression requiring treatment; 1) Evidence of progressive bone marrow failure: manifested as progressive reduction of hemoglobin and/or platelets. 2) Splenomegaly (such as>6 cm below the left rib margin) or symptomatic splenomegaly. 3) Massive lymph node enlargement (such as longest diameter>10 cm) or symptomatic lymph node enlargement. 4) Progressive lymphocytosis, such as lymphocytosis>50% within 2 months, or lymphocyte doubling time (LDT)38.0 ?, = 2 weeks; (4) No evidence of infection, night sweats>1 month. 2. Received systemic or local treatment, including chemotherapy or radiotherapy, before enrollment 3. Patients or their families strongly demand treatment; 4. Accompanied by other malignant tumors that require treatment or affect survival. 5. Expected survival period<3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to First Treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival;Overall Survival;Rate of Disease Progression;Quality of Life;Change of Clinical Characteristics;Change of Cytology;Change of Cytogenetics;Change of Molecular Biology; | — |
Countries
China
Contacts
Public ContactYu WenJuan
The First Affiliated Hospital, Zhejiang University College of Medicine
Outcome results
None listed